<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04906213</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00107752</org_study_id>
    <nct_id>NCT04906213</nct_id>
  </id_info>
  <brief_title>CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients</brief_title>
  <acronym>CREST-KT</acronym>
  <official_title>CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      CREST-KT is a single-center, double-blinded, randomized trial of dapagliflozin therapy in 72&#xD;
      kidney transplant recipients with (n=36) and without type 2 diabetes (n=36). After evenly&#xD;
      dividing patients by type 2 diabetes diagnosis, patients will be randomized 2:1 to&#xD;
      dapagliflozin 10mg versus placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A screening visit will occur at which time an informed consent will be obtained and&#xD;
      eligibility determined. Women of child bearing potential will have a serum pregnancy test&#xD;
      performed. This will be followed by a baseline visit. A renal biopsy and a 3D echocardiogram&#xD;
      will be performed. At the next visit randomization will be performed and the subjects will&#xD;
      receive their study medication, either dapagliflozin or a placebo. Following the&#xD;
      randomization visit the subject will return every 3 months (visits 2-7) for a total of 6&#xD;
      visits spanning 18 months. At each visit vital signs and weight will be taken. Other&#xD;
      procedures include labs drawn for hematology, basic chemistry, coagulation, Glycated&#xD;
      hemoglobin and serum insulin. A 3 D echocardiogram is repeated on Visits 4 and 6. A renal&#xD;
      biopsy is repeated on Visit 3.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Placebo-controlled, double-blind, randomized clinical trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in kidney function as measured by eGFR</measure>
    <time_frame>Baseline, 6 months, 9 months, 12 months and 18 months</time_frame>
    <description>eGFR will be measured by blood test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in kidney function as measured by albuminuria</measure>
    <time_frame>Baseline, 6 months, 9 months, 12 months and 18 months</time_frame>
    <description>Albuminuria will be measured by urine Albumin/Creatinine Ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in cardiac structure</measure>
    <time_frame>Baseline, month 9 and month15</time_frame>
    <description>Cardiac structure as measured by the 3D echocardiogram</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood insulin level</measure>
    <time_frame>Baseline, month 6 and month 18</time_frame>
    <description>Blood insulin level will be determined lab values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in fasting blood sugar</measure>
    <time_frame>Baseline, month 6 and month 18</time_frame>
    <description>Fasting Blood sugar will be determined lab values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Urinary Tract infections</measure>
    <time_frame>up to 18 months</time_frame>
    <description>Data to be gathered from chart review and patient report</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Genital infections</measure>
    <time_frame>up to 18 months</time_frame>
    <description>Data to be gathered from chart review and patient report</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in kidney biopsy as measured by percentage of interstitial fibrosis</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Hemoglobin A1C as measured by blood work</measure>
    <time_frame>Baseline, Months 3,6,9,12,15 and 18</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events will be collected form the medical record and patient report</measure>
    <time_frame>up to 18 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Kidney Transplant; Complications</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Arm I: With Type II Diabetes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Kidney Transplant recipient with Type II diabetes, randomized to either dapagliflozin or a placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Without Diabetes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Kidney Transplant recipient without Type II diabetes, randomized to either dapagliflozin or a placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10Mg Tab</intervention_name>
    <description>Dapagliflozin 10 Mg daily or placebo daily for 18 months</description>
    <arm_group_label>Arm 2: Without Diabetes</arm_group_label>
    <arm_group_label>Arm I: With Type II Diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>10Mg Placebo Tab</description>
    <arm_group_label>Arm 2: Without Diabetes</arm_group_label>
    <arm_group_label>Arm I: With Type II Diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Equal to or greater than 12 months and up tp 60 months post kidney transplant&#xD;
&#xD;
          2. Estimated glomerular filtration rate (eGFR) equal to or greater than 30ml/min/1.73m&#xD;
             squared at screening&#xD;
&#xD;
          3. Standard immunosuppression, including calcineurin inhibitor, Mycophenolate Mofetil or&#xD;
             Sodium and a glucocorticoid&#xD;
&#xD;
          4. Able to provide written consent -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Type I diabetes&#xD;
&#xD;
          2. Any other solid organ transplant&#xD;
&#xD;
          3. Hemoglobin A1c greater than 12 %&#xD;
&#xD;
          4. SGLT2i use at the time of enrollment&#xD;
&#xD;
          5. Prior SGLT2i allergy or intolerance&#xD;
&#xD;
          6. Pregnant or nursing at the time of enrollment&#xD;
&#xD;
          7. History of antibody medicated rejection (AMR) or a Banff score greater than 2B for&#xD;
             acute cellular rejection (ACR)&#xD;
&#xD;
          8. Active anticoagulant use other than aspirin 81 mg for primary prevention of&#xD;
             cardiovascular disease&#xD;
&#xD;
          9. Known positive donor-specific antibodies prior to enrollment&#xD;
&#xD;
         10. Uncircumcised men&#xD;
&#xD;
         11. Greater than 2 urinary tract infections (UTI) over the 12 months prior to enrollment&#xD;
&#xD;
         12. Any genital infections over the 12 months prior to enrollment -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myles Wolf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Research Coordinator</last_name>
    <phone>919-681-4990</phone>
    <email>Adi.molvin@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Edmonston, MD</last_name>
    <phone>919-668-4596</phone>
    <email>daniel.edmonston@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Adi Molvin, BSN</last_name>
      <phone>919-681-4990</phone>
      <email>Adi.molvin@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Edmonston, MD</last_name>
      <phone>919-668-4956</phone>
      <email>Daniel.edmonston@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Myles Wolf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Stoumpos S, Jardine AG, Mark PB. Cardiovascular morbidity and mortality after kidney transplantation. Transpl Int. 2015 Jan;28(1):10-21. doi: 10.1111/tri.12413. Epub 2014 Aug 20. Review.</citation>
    <PMID>25081992</PMID>
  </results_reference>
  <results_reference>
    <citation>Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2016 Mar 17;374(11):1094. doi: 10.1056/NEJMc1600827.</citation>
    <PMID>26981940</PMID>
  </results_reference>
  <results_reference>
    <citation>Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.</citation>
    <PMID>28605608</PMID>
  </results_reference>
  <results_reference>
    <citation>Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE-TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10.</citation>
    <PMID>30415602</PMID>
  </results_reference>
  <results_reference>
    <citation>Halden TAS, Kvitne KE, Midtvedt K, Rajakumar L, Robertsen I, Brox J, Bollerslev J, Hartmann A, Ã…sberg A, Jenssen T. Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus. Diabetes Care. 2019 Jun;42(6):1067-1074. doi: 10.2337/dc19-0093. Epub 2019 Mar 12.</citation>
    <PMID>30862658</PMID>
  </results_reference>
  <results_reference>
    <citation>Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation. 2016 Sep 6;134(10):752-72. doi: 10.1161/CIRCULATIONAHA.116.021887. Epub 2016 Jul 28. Review.</citation>
    <PMID>27470878</PMID>
  </results_reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>May 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post operative kidney transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual data will not be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

